Correcting Diagnostic Assumptions in Pediatric Allergy
A landmark Australian study has revealed that clinical history and preliminary testing are frequently insufficient for accurately diagnosing peanut allergies in infants. Research published on November 4, 2026, in The Journal of Allergy and Clinical Immunology: In Practice, found that 35 percent of infants previously suspected of having a peanut allergy showed no reaction during a supervised oral food challenge. This diagnostic shift, led by the Murdoch Children’s Research Institute (MCRI) and the National Allergy Centre of Excellence (NACE), suggests that many children are unnecessarily subjected to long-term dietary restrictions.
The findings are based on the ongoing evaluation of the ADAPT Peanut Oral Immunotherapy Program, which launched in 2024 as the first public hospital-based treatment program for infants outside of clinical trial settings. Between 2024 and 2026, researchers assessed 1,275 infants under the age of 18 months across hospitals in Victoria, New South Wales, Queensland, South Australia, and Western Australia. Of these, 778 underwent a supervised oral food challenge—a procedure where infants are given gradually increasing doses of peanut in a controlled medical environment to monitor for reactions.
The Role of Supervised Challenges
For decades, many pediatric allergy diagnoses have relied heavily on skin prick tests and blood work, which measure sensitization rather than clinical tolerance. Dr. Tim Brettig, MCRI Population Allergy Group Senior Research Clinician and ADAPT Medical Lead, reported in an article published by News-Medical that these initial tests often lead to “false positives” regarding actual allergic reactions. By conducting supervised challenges, clinicians can definitively identify which infants are tolerant to peanuts, thereby sparing them and their families the psychological and practical burden of strict dietary avoidance.
The study demonstrated that while 65 percent of the tested infants did experience a reaction—including 12 percent who suffered anaphylaxis—every episode was managed safely by medical teams. Conversely, the 35 percent of infants who showed no reaction were cleared to resume a normal diet, including the consumption of peanut-based foods. This process not only removes the “allergy” label but also clarifies the care path for those who are truly allergic, as 97.5 percent of those who reacted were able to successfully transition to oral immunotherapy, a treatment designed to build long-term tolerance through daily, controlled exposure.
Institutional and Clinical Implications
Australia reports some of the highest childhood food allergy rates globally, with peanut allergy affecting approximately one in 30 children. Professor Kirsten Perrett, MCRI Population Allergy Group Leader and NACE Director, emphasized that the data necessitates a change in standard clinical practice. She noted that oral food challenges are not currently used routinely for every infant with a suspected allergy, but the evidence suggests they should be considered a mandatory step before initiating immunotherapy or imposing permanent dietary bans.
For families like the parents of one-year-old Arthur, who underwent the process at The Royal Children’s Hospital, the challenge provided a definitive answer after initial testing suggested a high risk of anaphylaxis. Despite early signs of hives and redness, Arthur tolerated the supervised challenge, allowing his family to move past the uncertainty of a suspected allergy. This outcome underscores the importance of accessibility; the NACE and National Allergy Council, funded by the Federal Government in 2022, are working to expand such specialized care to improve health outcomes and reduce the impact of allergic disease on children across both metropolitan and regional areas.